Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924911 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study in Healthy Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00924911 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 20 participants.
The verdict
NCT00924911, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation. Pharmacokinetics of these three tablets will be evaluated and the investigation tablet with the optimal PK profile will be progressed to Part 2. In Part 2 the investigational tablet selected from Part 1 will be coadministered with food alone, an H2 blocker alone, or an H2 blocker given in combination with ascorbic acid to evaluate the effect on GSK1322322 pharmacokinetics. Plasma GSK1322322 PK profile, safety, and tolerability will be assessed from each dose group.
Interventions
- DRUG GSK1322322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-04-27 |
| Est. Completion | 2009-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924911
The ClinicalTrials.gov registry entry for NCT00924911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1322322 is the first listed.
NCT00924911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924911 about?
NCT00924911 is a clinical study titled "Relative Bioavailability Study in Healthy Subjects". Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation. Pharmacokinetics of these three tablets will be evaluated and the investigation tablet with the optimal PK profile will be prog...
What is the current status of trial NCT00924911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-04-27. Estimated completion is 2009-07-09.
What interventions are being tested in trial NCT00924911?
The interventions under investigation include: GSK1322322 (DRUG).
Who is sponsoring clinical trial NCT00924911?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.